PANDURANGA VENKATARAMANA: Open Payments
NPI 1891815775 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$368 in 12 payments from 7 companies in 2025. Trend: 2023 $400 · 2024 $711 · 2025 $368
Food & beverage: $368
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 6 | $153 |
| E.R. Squibb & Sons, L.L.C. | 1 | $87 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
Products named: INVEGA SUSTENNA, COBENFY, UZEDY, ABILIFY MAINTENA, CAPLYTA, SPRAVATO, ERZOFRI EXTENDED-RELEASE.
Industry payments across PA — which companies pay providers there.
